ストックスクリーナーアプリを入手
13.09
2.35%
0.30
アフターアワーズ：
13.09
Tourmaline Bio Inc (TRML) 最新ニュース
Brokers Issue Forecasts for Tourmaline Bio FY2024 Earnings - MarketBeat
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Lifesci Capital Begins Coverage on Tourmaline Bio (NASDAQ:TRML) - MarketBeat
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - Nasdaq
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
StockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Buy - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of “Buy” by Analysts - Defense World
ClearOne (NASDAQ:CLRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Broadway Financial (NASDAQ:BYFC) Now Covered by StockNews.com - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 16.3% in January - MarketBeat
TrueBlue (TBI) Expected to Announce Earnings on Wednesday - Armenian Reporter
Andersons (ANDE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2024 Earnings - MarketBeat
Leerink Partnrs Weighs in on Tourmaline Bio FY2029 Earnings - MarketBeat
Bleakley Financial Group LLC Purchases 110 Shares of Choice Hotels International, Inc. (NYSE:CHH) - Defense World
In the crowded cardio space, it’s David vs. Goliath for small biotechs - PharmaVoice
Jennison Associates LLC Trims Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio Inc (TRML) Stock Showcases -13.66% 20-Day Moving Average - The News Heater
TRML’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Solventum Corp (SOLV) Shares Down Despite Recent Market Volatility - The News Heater
Tourmaline Bio Inc (TRML) Becoming More Attractive for Investors - Knox Daily
In the Green: JBDI Holdings Ltd (JBDI) Closes at 0.65, Up/Down 11.02 from Previous Day - The Dwinnex
Closing Bell Recap: E.W. Scripps Co (SSP) Ends at 1.88, Reflecting a 6.82 Upturn - The Dwinnex
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Daily Market Movement: Tourmaline Bio Inc (TRML) Sees a 6.37 Increase, Closing at 16.53 - The Dwinnex
Keeping an Eye on Entegris Inc (ENTG) After Insider Trading Activity - Knox Daily
Potential Price Increase for Monster Beverage Corp (MNST) After Recent Insider Activity - Knox Daily
Recent Insider Activity Suggests Potential Gains for Vita Coco Company Inc (COCO) - Knox Daily
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8% - MarketBeat
JPMorgan Chase & Co. Acquires 2,100 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
Graves Ophthalmopathy Market to Expand Significantly by 2034, - openPR
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference - Marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Graves' Disease Market Size in the 7MM was ~USD 4,400 million - openPR
Cantor Fitzgerald Estimates Tourmaline Bio FY2025 Earnings - Defense World
Brokers Issue Forecasts for Tourmaline Bio FY2025 Earnings - MarketBeat
0.22%
0.81%
大文字化:
|
ボリューム (24 時間):